Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: RVTY

Revvity, Inc.

Healthcare | Medical - Diagnostics & Research
$83.03 -3.75 (-4.32%) as of 2026-07-14 16:14 UTC
Market Cap$9.3B
EPS (TTM)$2.07

Revvity, Inc. (NYSE: RVTY) is a $9.3B medical - diagnostics & research company trading at $83.03 (−4.3% today) — 40.1× trailing earnings, yielding 0.34%. Figures from SEC EDGAR and market feeds; updated 2026-07-14 16:14 UTC.

52-Week Range
Low $82.79High $97.07

What Revvity, Inc. does

Revvity is a health science company headquartered in Waltham, Massachusetts that provides technologies, expertise and services supporting scientific research and medical applications from discovery through diagnosis and treatment. The company operates in two business segments—Life Sciences and Diagnostics—and serves pharmaceutical, biotech, contract research, academic and government institutions globally.

Summarized from Revvity, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$83.03
Change (1D)-3.75 (-4.32%)
Market cap$9.3B
52-week range$82.79 – $97.07
Valuation
P/E (TTM)40.11×
EV/EBITDA14.50×
EPS (TTM)$2.07
Dividend yield0.34%
Price/book1.29×
Return on equity3.33%
Debt/equity0.36
Returns
52-week return+0.3%
Revenue, margins & earnings
FY2021 Net income: $728MFY2021 Taxes & interest: $139MFY2021 Operating costs: $2.92B$3.78BFY2021FY2022 Net income: $943MFY2022 Taxes & interest: $315MFY2022 Operating costs: $2.57B$3.83BFY2022FY2023 Revenue: $3.31B — margin split not shown (non-operating gains)$3.31BFY2023FY2024 Net income: $270MFY2024 Taxes & interest: $76MFY2024 Operating costs: $2.41B$2.76BFY2024FY2025 Net income: $241MFY2025 Taxes & interest: $115MFY2025 Operating costs: $2.50B$2.86BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-06-17
  • 2026-06-17Gonzales AnitaVice President and CAOF-33$3.3K
  • 2026-05-11Witz PascaleA1,015—
  • 2026-05-11Witz PascaleA1,265—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • T. Rowe Price Investment Management, Inc.22,198,422$1.94B+40.1%
  • VANGUARD GROUP INC12,792,509$1.24B-5.4%
  • PRICE T ROWE ASSOCIATES INC /MD/10,090,158$884.00M+17.2%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Revvity, Inc. do?

Revvity is a health science company headquartered in Waltham, Massachusetts that provides technologies, expertise and services supporting scientific research and medical applications from discovery through diagnosis and treatment.

What is RVTY's valuation?

RVTY trades at $83.03, 40.11× trailing earnings, 14.50× EV/EBITDA, as of 2026-07-14. It carries a 0.34% dividend yield.

When did RVTY last file with the SEC?

Revvity, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-05-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 16:14 UTC. This page is also available as JSON at /api/data?ticker=RVTY and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RVTY and 3,500+ tickers.

Create a free account — keep RVTY
For your agent
GET /api/data?ticker=RVTY

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt